Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer

Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer

Purpose: Data from the CT-P16 3.1 study demonstrated equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) for the primary endpoint of objective response rate (ORR) during induction treatment in patients with metastatic or recurren...

Full description

Saved in:
Bibliographic Details
Main Authors: Zoran Andric, Fedor Moiseenko, Tamta Makharadze, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Hana Ju, Eric Hyungseok Baek, Soonbum Kwon, IlSung Chang, SinHye Kim, HyunAh Kim, EunKyung Lee, Claire Verschraegen
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Bevacizumab
Biosimilar
CT-P16
NSCLC
Anti-VEGF
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225001066
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468294225001066

Similar Items